Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03437928 · ClinicalTrials.gov registry record · NA

DBS for Depression

A NA study of Major Depressive Disorder, sponsored by Baylor College of Medicine.

Recruiting
Registry status
NA
Development phase
12
Enrollment target
2
Study locations

NCT03437928: Recruiting NA study of Major Depressive Disorder, sponsored by Baylor College of Medicine.

NCT03437928 is a NA study of Major Depressive Disorder that is actively recruiting participants, run by Baylor College of Medicine. The registered enrollment target is 12 participants, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03437928, a NA study of Major Depressive Disorder, is actively recruiting participants, sponsored by Baylor College of Medicine.

RECRUITING
Registry status
NA
Development phase
12 participants
Enrollment target
2
Study locations

Study Summary

The goal of the study is to address the unmet need of TRD patients by identifying brain networks critical for treating depression and to use next generation precision DBS with steering capability to engage these targeted networks. The study's goal will be achieved through 3 specific aims: 1. Demonstrate device capability to selectively and predictably engage distinct brain networks 2. Delineate depression-relevant networks and demonstrate behavioral changes with network-targeted stimulation 3. Demonstrate that chronic DBS using steered, individualized targeting is feasible and safe for reducing depressive symptoms

Primary Outcome

Response will be defined as 50% decrease in Montgomery-Asberg Depression Rating Scale (MADRS) from baseline. The range is from 0 to 60 and a score higher than 20 indicates moderate to severe depression.

Conditions Studied

Interventions

  • DEVICE Directional Deep Brain Stimulation

Study Locations (2)

Texas

  • University of Texas Southwestern - Dallas
  • Baylor College of Medicine - Houston

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2019-08-20
Est. Completion 2026-08-19
Phase NA
Baylor College of Medicine

616 total trials

What NCT03437928 shows while recruiting

NCT03437928 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 1 intervention - of which Directional Deep Brain Stimulation is the first listed.

NCT03437928 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT03437928 about?

NCT03437928 is a clinical study titled "DBS for Depression". The goal of the study is to address the unmet need of TRD patients by identifying brain networks critical for treating depression and to use next generation precision DBS with steering capability to engage these targeted networks. The study's goal will be achieved through 3 specific aims: 1. Demons...

What is the current status of trial NCT03437928?

This trial is currently recruiting. It is a NA study. The enrollment target is 12 participants. The study started on 2019-08-20. Estimated completion is 2026-08-19.

What conditions does trial NCT03437928 study?

This clinical trial studies the following conditions: Major Depressive Disorder.

What interventions are being tested in trial NCT03437928?

The interventions under investigation include: Directional Deep Brain Stimulation (DEVICE).

Who is sponsoring clinical trial NCT03437928?

This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03437928 being conducted?

This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Major Depressive Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03437928's enrollment target sits among peer trials

12 265th of 282 higher than 15 of 282 other Major Depressive Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT02619448 · 12 participants · Early Phase 1

    Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03437928, the US trial registry maintained by the National Library of Medicine. NCT03437928 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.